Looking to publish in Annals Of Oncology? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Try Livewrite NowAnnals of Oncology is the official journal of the European Society for Medical Oncology and the Japanese Society of Medical Oncology. It publishes innovative cancer treatments and translational work related to oncology and precision medicine, with particular focus on systemic anticancer therapy, randomized trials, guidelines, molecular pathology, bioinformatics, modern statistics, and biotechnologies.
Looking to publish in Annals Of Oncology? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Try Livewrite NowSubmission Instructions
Annals Of Oncology accepts the following article types. Click on an article type to view submission instructions.
Original Articles
Reviews
Letters To The Editor
In Brief Trial Updates
Recent Publications
Preclinical characterization and phase 1 results of TQB2102, a first-in-class HER2 biparatopic antibody-drug conjugate, in patients with advanced solid tumors
D.Y. Ruan, S.Y. Lin, J.J. Huang, Y.H. Li, N. Li, X.J. Qu, X.B. Du, Y.M. Yin, Z.Y. Yuan, Y.X. Shi, F. Xu, X. An, R.X. Hong, W. Xia, C. Xue, X.W. Bi, K.K. Jiang, Q.F. Zheng, Y.Q. Zhang, J.J. Peng, Z.Y. Liu, H.H. Xiong, A.L. Suo, R.B. Lin, S. Zhang, S.N. Tang, Y. Yu, X. Li, X. Wang, X. Tian, P. Lv, C. Shen, L.G. Lou, L. Wang, Z.P. Zhang, T.J. Xu, T.X. Chen, S.S. Wang, R.H. Xu
When artificial intelligence learns to abstain: towards clinically responsible diagnostic support in liver pathology
M. Svrcek, L. Verlingue
A chemotherapy-free, pathological response-adapted strategy using trastuzumab–pertuzumab and T-DM1 in HER2-positive early breast cancer: the PHERGain-2 study
L. Garrigós, M. Ruiz-Borrego, J.M. Pérez-García, A. Guerrero-Zotano, A. Cortés-Salgado, S. Kuemmel, M. Colleoni, C. Reboredo-Rendo, B. Bermejo, I. Blancas, J. Gavila, A. Fabi, C. Morales, A. Stradella, V. Carañana, E. Martínez-de Dueñas, C. Albacar, O. Ballesteros-Cidras, G. Martrat, S. Iacobucci, O. Boix, P. Berenguer-Molins, D. Alcalá-López, J. Cortés, A. Llombart-Cussac, L. Garrigós, M. Ruiz-Borrego, J.M. Pérez-García, Á. Guerrero-Zotano, A. Cortés-Salgado, S. Kümmel, M. Colleoni, C. Reboredo-Rendo, B. Bermejo, I. Blancas, J. Gavila, A. Fabi, C. Morales, A. Stradella, V. Carañana, E. Martínez-de Dueñas, C. Albacar, S. Escrivá-de-Romaní, A. Musolino, E. Galve-Calvo, V. Quiroga, O. Gluz, A. López González, J. Ponce-Lorenzo, M. Cazzaniga, D. Fischer, P. Cortez-Castedo, P. Sanchez-Rovira, S. Morales, C. Zamagni, V. Iranzo, E. Collovà, A. Santaballa, L. Cavanna, O. Hoffmann, A. Bassam, J.Á. García-Sáenz, A. Medina, M. Palka, Y. Al-Farhat, O. Ballesteros-Cidras, G. Martrat, S. Iacobucci, O. Boix, P. Berenguer-Molins, D. Alcalá-López, J. Cortés, A. Llombart-Cussac
Corrigendum to ‘Subcutaneous versus intravenous nivolumab for renal cell carcinoma’
L. Albiges, M.T. Bourlon, M. Chacón, H.J. Cutuli, Y.A.L. Chuken, B. Zurawski, J.M. Mota, I. Magri, M. Burotto, M. Luz, J. de Menezes, E.P.Y. Ruiz, S. Fu, M. Richardet, B.P. Valderrama, M. Maruzzo, S. Bracarda, M. Breckenridge, H.E. Vezina, D. Rathod, Z. Yu, Y. Zhao, M. Dixon, D. Perumal, S. George
Survival outcomes in POD1UM-303/InterAACT-2: a phase 3 study of retifanlimab plus carboplatin–paclitaxel in first-line advanced squamous anal cancer
S. Rao, E. Samalin-Scalzi, L. Evesque, M. Ben Abdelghani, F. Morano, A. Roy, L. Dahan, S. Tamberi, A.S. Dhadda, M.G. Zampino, N. Casanova, R. Guimbaud, A. Lievre, J. Maurel, P. Zhang, M.C. Munteanu, M. Jones, C. de la Fouchardiere, A. Takashima, M. Fakih, J. Spano
Frequently asked questions
How long does it take to publish?
3 days from submission to first decision; 45 days from submission to acceptance for accepted papers (median).
Reformat to Annals Of Oncology using Livewrite PremiumIs a cover letter required?
A letter is required with manuscript submission stating that the report is not under consideration elsewhere and that all named authors have agreed to submission. Pre-submission enquiries require a short cover letter.
Reformat to Annals Of Oncology using Livewrite PremiumWhat are the publication costs?
This journal has no page charges. Open access publishing options are available.
Reformat to Annals Of Oncology using Livewrite Premium